Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Patent
1994-06-14
1997-04-22
Eisenschenk, Frank C.
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
435 7021, 435 702, 435328, 4353441, 5303913, 53038885, 5303888, 5303873, C07K 1628, C07K 1630, C12N 512
Patent
active
056228368
ABSTRACT:
The present invention relates to a family of novel antigens associated with malignant cells of bladder carcinomas, and to antibodies, portions or fragments thereof, or single domain antibodies which recognize those antigens. The invention provides methods of detecting bladder carcinomas using those antibodies, fragments or portions thereof, or single domain antibodies, to kits for use in those methods and to methods of treating bladder carcinoma using the antibodies, fragments or portions thereof, or single domain antibodies.
REFERENCES:
patent: 4643971 (1987-02-01), Fradet et al.
Harris et al., TIBTECH, 11:42, 1993, Therapeutic . . . Age.
Waldmann, Monoclonal Ab . . . Therapy, Science, 1991, 252:1657-62.
Walker et al, Detection of . . . Assay, J. Urol., 1989, 142:1578-83.
Bander NH., Monoclonal Antibodies In Urologic Oncology. Cancer 60:658-667 (1987).
Boniface GR, Izard ME, Walker KZ, McKay DR, Sorby PJ, Turner JH and Morris JG. Labelling of monoclonal antibodies with Samarium-153 for combined radioimmunoscintigraphy and radioimmunotherapy. J. Nucl. Med. 30(5):683-691 (1989).
Chopin DK, deKernion JB, Rosenthal DL and Fahey JL. Monoclonal antibodies against transitional cell carcinoma for detection of malignant urothelial cells in bladder washing. J. Urol. 134:260.265 (1985).
Cloutier RJ and Watson EE. Radiation dose from radioisotopes in the blood. In Medical Radionuclides: radiation dose and effects, ORNLC 691212. Eds: Cloutier RJ, Edwards CL and Snyder WS. Oak Ridge National Laboratory, Oak Ridge. pp. 325.346 (1970).
Early PJ and Sodee DB. Dosimetry. In: Principles and Practice of Nuclear Medicine. CV Mosby Co, Toronto. pp. 113-130 (1985).
Edwards PAW, Smith CM, Neville AM and O'Hare MJ. A human-human hybridoma system based on a fast-growing mutant of the ARH.77 plasma cell leukemiadeviced line. Eur. J. Immunol. 12:641-648 (1982).
Feller PA and Sodd VJ. Dosimetry of four heart imaging radionuclides: 43K, 81Rb, 129Cs and 201Tl J. Nucl. Med. 16(11):1070.1075 (1975).
Hakomori S. Tumor-associated carbohydrate antigens. Ann. Rev. Immunol. 2:103.126 (1984).
Huland H, Otto U and Droese M. The value of urinary cytology, serum and urinary carcinoembryonic antigen, rheumatoid factors, and urinary immunoglobulin concentration as tumour markers or prognostic factors in predicting progression of superficial bladder cancer. Eur. Urol. 9:346.349 (1983).
Kohler G and Milstein C. Derivation of specific antibody-producing tissue culture and tumour lines by cell fusion. Eur. J. Immunol. 6:511.519 (1976).
Ledeen RW and Yu RK. Gangliosides: structure, isolation and analysis. Meth. Enzymol. 83:139-191 (1982).
Limas C and Lange P. Altered reactivity for A, B, H antigens in transitional cell carcinomas of urinary bladder. A study of the mechanisms involved. Cancer 46:1366.1373 (1980).
Longin A, Huazi A, Berger.Dutrieux N, Escourrou G, Bouvier R, Richer G, Mironneau I, Fontaniere B, Devonec M and Laurent JC. A monoclonal antibody (BL2.10Dl) reacting with a bladder cancer.associated antigen. Int. J. Cancer 43:183.189 (1989).
Magnani JL, Brockhaus M, Smith DF, Ginsburg V, Blaszczyk M, Mitchell KF, Steplewski Z and Koprowski H. A mosialoganglioside is a monoclonal antibody-defined antigen of color carcinoma. Science 212:55.56 (1981).
Masuko T, Yagita H and Hashimoto Y. Monoclonal antibodies against cell surface antigens present on human urinary bladder cancer cells. J. Nat. Cancer Inst. 72(3):523.530 (1984).
McCabe RP, Haspel MV, Potamo N and Hanna MG. Monoclonal antibodies in the detection of bladder cancer. In Cancer Diagnosis In Vitro using Monoclonal Antibodies Ed. HZ Kupchik. Marcel Dekker Inc., New York. pp. 1.29 (1988).
Murphy WM, Soloway MS, Jukkola AF, Crabtree WN and Ford KS. Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms. Cancer 53:1555.1565 (1984).
Myers, M.J. Dosimetry for radiolabelled antibodies--macro or micro? Int. J. Cancer. Supplement 2, 71.73 (1988).
Piccoli G, Varese D and Rotienno M. Diagnosis and clinical correlations in Nephrology. In: Atlas of Urinary Sediments. Raven Press, New York. pp. 48.49 (1984).
Ridell M, Minnikin DE, Partlett JH and Mattsby-Baltzer I. Detection of mycobacterial lipid antigens by a combination of thin-layer chromatography and immunostaining. Lett. Appl. Microbiol. 2:89.9210 (1986).
Russell PJ, Raghavan D, Gregory P, Phillips J, Wills EJ, Jelbart M, Wass J, Zbroja RA and Vincent PC. Bladder cancer xenografts: a model of tumour cell heterogeneity. Cancer Res. 46:2035-2040 (1986).
Russel PJ, Jelbart ME, Wills E, Singh S, Wass J, Wotherspoon J and Raghavan D. Establishment and characterization of a new human bladder cancer cell line showing features of squamous and glandular differentiation. Int. J. Cancer 41:74.82 (1988).
Russell PJ, Raghavan D, Philips J and Wills EJ. The biology of urothelial cancer. In The Management of Bladder Cancer. Ed. D Raghavan, Edward Arnold Publishers, London. pp. 1-41 (1988a).
Russell PJ, Wills EJ, Philips J, Jelbart M, Gregory P and Raghavan D. Features of squamous and adenocarcinoma in the same cell in a xenografted human transitional cell carcinoma: Evidence of a common histogenesis? Urol. Res. 16:79.84 (1988b).
Russell PJ, Wass J, Lukeis R, Garson OM, Jelbart M, Wills E, Philips J, Brown J, Carrington N, Vincent PC and Raghavan D. Characterisation of cell lines derived from a multiply aneuploid human bladder transitional-cell carcinoma, UCRU.BL.13.Int. J. Cancer. 44:276.285 (1989).
Sharkey RM, Kaltovich FA, Shih LB, F and I, Govelitz G and Goldenberg DM. Radioimmunotherapy of human colonic cancer xenografts with 90Y.labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res. 48:3270.3275 (1988).
Snyder WS, Ford MR, Warner GG and Watson SB. A tabulation of dose equivalent per microcurie-day for source and target organs of an adult for various radionuclides. In : ORNL.500. Oak Ridge National Laboratory, Oak Ridge. p. 3 (1974).
van Haafen.Day C, Russell P, Rugg C, Wills EJ and Tattersall MHN. Flow cytometric and morphological20 studies of ovarian carcinoma cell lines and xenografts. Cancer Res. 43:3725.3731 (1983).
van Haafen.Day C, Russell P, Carr S and Wright L. Development and characterization of a human cell line from an ovarian mixed mullerian tumor (carcinosarcoma). In Vitro Cell Dev. Biol. 24(10):965.971 (1988).
Vartdal F, Vandvik B and Lea T. Immunofluorescence staining of agarose.embedded cells. A new technique developed for immunological characterization of markers on a small number of cells. J. Immunol. Meth. 92:125.129 (1986).
Walker KZ, Gibson J, Axiak SM and Prentice RL. Potentiation of hybridoma production by the use of mouse fibroblast conditioned media. J. Immunol. Methods 88:75.81 (1986).
Walker KZ, Seymour.Munn K, Keech FK, Axiak SM, Bautovich GJ, Morris JG and Basten A. A rat model system for radioimmunodetection of kapp myeloma antigen on malignant B cells. Eur. J. Nucl. Med. 12:461.467 (1986).
Ward ES, Gaussan D, Griffiths AD, Jones PT and Winter G. Binding activities of a repertoire Of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544.546 (1989).
Zola H, Moore HA, Hunter IK and Bradley J. Analysis of chemical and biochemical properties of membrane molecules in situ by analytical flow cytometry with monoclonal antibodies. J. Immunol. Meth. 74:65.77 (1984a).
Zola H, Moore HA, Hohmann A, Hunter IK, Nikoloutsopoulos A and Bradley J. The antigen of mature human B cells detected by the monoclonal antibody FMC7 studies of the nature of the antigen and 20 modulation of its expression. J. Immunol. 133(1):321.326 (1984b).
Lightfoot et al., "Dosimetric and Therapeutic Studies in Nude Mice Xenograft Models with .sup.153 Samarium-Labelled Monoclonal Antibody, BLCA-38", Antibody, Immunoconjugates, And Radiopharmaceuticals, vol. 4, No. 3, (1991).
Patent Abstracts of Japan, C-601, p. 5, JP.A. 1-40500 (Takashi Masuko) 10 Feb. 1989.
Patent Abstracts of Japan, C-561, p. 105, JP.A. 63-230096 (Sumitomo Electric Ind Ltd) 26 Sep. 1988.
Fradet et al., "Polymorphic expression of a human superficial bladder tumor antigen defined by mouse m
Russell Pamela J.
Walker Karen Z.
Eisenschenk Frank C.
The Central Sydney Area Health Service
The University of Sydney
LandOfFree
Monoclonal antibodies which recognize malignant cells from bladd does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monoclonal antibodies which recognize malignant cells from bladd, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monoclonal antibodies which recognize malignant cells from bladd will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-340837